Hydrocortison Jenapharm (Hydrocortisone)

Hydrocortison Jenapharm is prescribed for several endocrine and inflammatory conditions where glucocorticoid activity is required.

• Treatment of primary or secondary adrenal insufficiency (Addison’s disease).
• Management of acute or chronic inflammatory disorders such as arthritis, colitis, or dermatitis.
• Suppression of severe allergic reactions, including anaphylaxis adjunct therapy.
• Replacement therapy during corticosteroid withdrawal to prevent adrenal crisis.
• Adjunctive therapy in certain autoimmune diseases when systemic anti‑inflammatory effect is needed.
• Short‑term use for exacerbations of respiratory conditions such as asthma or chronic obstructive pulmonary disease when systemic control is required.

• Hydrocortison Jenapharm delivers hydrocortisone, which binds to intracellular glucocorticoid receptors and translocates to the nucleus. The receptor‑ligand complex modulates gene transcription, up‑regulating anti‑inflammatory proteins such as annexin‑1 and down‑regulating pro‑inflammatory cytokines (e.g., IL‑1, IL‑6, TNF‑α). This genomic effect reduces leukocyte migration, vascular permeability, and immune activation, providing systemic anti‑inflammatory and immunosuppressive actions. Additionally, non‑genomic membrane‑mediated pathways contribute to rapid anti‑edematous effects.

Like other systemic glucocorticoids, hydrocortisone may cause a range of adverse reactions that vary in frequency, severity, and reversibility, and they often depend on dose and duration of therapy. Patients should be monitored regularly to detect early signs of these effects.

Common

• Increased appetite or weight gain.
• Fluid retention leading to mild edema.
• Elevated blood glucose levels, especially in diabetic patients.
• Mood changes such as irritability or insomnia.
• Skin thinning or easy bruising.
• Gastrointestinal discomfort or ulcer risk.

Serious

• Severe infection risk due to immunosuppression.
• Osteoporosis or bone fracture with prolonged use.
• Adrenal suppression causing crisis on abrupt discontinuation.
• Hypertension or cardiovascular events.
• Psychiatric disturbances such as psychosis (rare).

When prescribing Hydrocortison Jenapharm, clinicians should consider several precautionary measures to minimize risk and ensure safe use.

• Assess adrenal function before initiating therapy, especially in patients with known insufficiency.
• Use the lowest effective dose for the shortest duration required.
• Monitor blood glucose and blood pressure regularly during treatment.
• Evaluate bone health and consider calcium/vitamin D supplementation for long‑term use.
• Review concomitant medications that may increase infection risk or affect cortisol metabolism.
• Caution in patients with a history of psychiatric disorders, as glucocorticoids can exacerbate symptoms.
• Avoid abrupt discontinuation; taper gradually to prevent adrenal crisis.

Hydrocortison Jenapharm can interact with other medicines that affect cortisol metabolism or increase the risk of adverse effects.

Avoid

• Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may reduce hydrocortisone plasma levels.
• Concurrent use of other systemic glucocorticoids, which can amplify immunosuppression and metabolic side effects.

Use with caution

• Anticoagulants (e.g., warfarin) because glucocorticoids may alter INR.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase gastrointestinal ulcer risk.
• Vaccines, especially live attenuated vaccines, due to possible reduced immune response.
• Diabetic agents, as hydrocortisone can raise blood glucose and may require dose adjustment.
• Antifungal azoles (e.g., ketoconazole) that inhibit CYP3A4 and may increase hydrocortisone exposure.